ESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results

from EAU Podcasts · host European Association of Urology

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Christof Vulsteke (BE) on the design and results of the phase III KEYNOTE 905/EV303 study: Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Episode metadata supplied by the publisher feed · Published Oct 22, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

ESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results

0:00 13:08

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of EAU Podcasts?

This episode is 13 minutes long.

When was this EAU Podcasts episode published?

This episode was published on October 22, 2025.

Can I download this EAU Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!